“Diabetes Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Diabetes Market.
The Diabetes Pipeline report provides a thorough commercial and clinical evaluation of pipeline products, spanning from pre-clinical development to market availability. It includes a comprehensive overview of each drug, encompassing its mechanism of action, clinical studies, potential NDA approvals, and various product development aspects such as technology, collaborations, mergers, acquisitions, funding, designations, and other pertinent details.
Some of the key takeaways from the Diabetes Pipeline Report:
-
Companies across the globe are diligently working toward developing novel Diabetes treatment therapies with a considerable amount of success over the years.
-
Diabetes companies working in the treatment market are Eli Lilly and Company, Regor Pharmaceuticals Inc., AstraZeneca, Eccogene, Pfizer, Sciwind Biosciences USA Co., Ltd., MediciNova, Sparrow Pharmaceuticals, HighTide Biopharma Pty Ltd, Novo Nordisk A/S, Biomea Fusion Inc., Altimmune, Inc., Novartis, Amgen, Neuraly, Inc., Carmot Therapeutics, Inc., Inventiva Pharma, Inversago Pharma Inc, Applied Therapeutics, Inc., and others, are developing therapies for the Diabetes treatment
-
Emerging Diabetes therapies in the different phases of clinical trials are- Tirzepatide/LY3298176, Danuglipron, RGT001-075, AZD0186, ECC5004, PF-07081532, XW014, MN-001, SPI-62, HTD1801, Semaglutide, BMF-219, ALT-801, MBL949, LY3457263, AMG 133, DD01, CT-868, IVA337, INV-202, AT-001, and others are expected to have a significant impact on the Diabetes market in the coming years.
-
In April 2025, Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company specializing in the development of novel peptide-based therapies, has announced the enrollment of the first participant in its Phase 2b ZUPREME-2 trial. This study targets individuals with overweight or Type 2 Diabetes and type 2 diabetes, evaluating the efficacy and safety of once-weekly subcutaneous doses of petrelintide, a long-acting amylin analogue, in comparison to a placebo.
-
In February 2025, Tandem Diabetes Care has received FDA clearance for its Control-IQ+ automated insulin delivery system, now approved for use in individuals with type 2 diabetes.
-
In February 2025, Sotagliflozin, which has FDA approval for treating type 2 diabetes and kidney disease, has demonstrated a substantial reduction in the risk of heart attack and stroke among high-risk patients, presenting a promising option for cardiovascular protection.
-
In January 2025, The FDA approved a new indication for semaglutide to help lower the risk of kidney disease progression, kidney failure, and cardiovascular death in adults with type 2 diabetes and chronic kidney disease, as announced by Novo Nordisk.
Diabetes Overview
Diabetes is a chronic medical condition that occurs when the body cannot properly regulate blood sugar (glucose) levels. It results from either insufficient insulin production (a hormone that helps glucose enter cells for energy) or the body’s inability to use insulin effectively.
Get a Free Sample PDF Report to know more about Diabetes Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/diabetes-pipeline-insight
Emerging Diabetes Drugs Under Different Phases of Clinical Development Include:
-
Tirzepatide/LY3298176: Eli Lilly and Company
-
Danuglipron: Pfizer
-
RGT001-075: Regor Pharmaceuticals Inc.
-
AZD0186: AstraZeneca
-
ECC5004: Eccogene
-
PF-07081532: Pfizer
-
XW014: Sciwind Biosciences USA Co., Ltd.
-
MN-001: MediciNova
-
SPI-62: Sparrow Pharmaceuticals
-
HTD1801: HighTide Biopharma Pty Ltd
-
Semaglutide: Novo Nordisk A/S
-
BMF-219: Biomea Fusion Inc.
-
ALT-801: Altimmune, Inc.
-
MBL949: Novartis
-
LY3457263: Eli Lilly and Company
-
AMG 133: Amgen
-
DD01: Neuraly, Inc.
-
CT-868: Carmot Therapeutics, Inc.
-
IVA337: Inventiva Pharma
-
INV-202: Inversago Pharma Inc
-
AT-001: Applied Therapeutics, Inc.
Diabetes Route of Administration
Diabetes pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
-
Oral
-
Intravenous
-
Subcutaneous
-
Parenteral
-
Topical
Diabetes Molecule Type
Diabetes Products have been categorized under various Molecule types, such as
-
Recombinant fusion proteins
-
Small molecule
-
Monoclonal antibody
-
Peptide
-
Polymer
-
Gene therapy
Diabetes Pipeline Therapeutics Assessment
-
Diabetes Assessment by Product Type
-
Diabetes By Stage and Product Type
-
Diabetes Assessment by Route of Administration
-
Diabetes By Stage and Route of Administration
-
Diabetes Assessment by Molecule Type
-
Diabetes by Stage and Molecule Type
DelveInsight's Diabetes Report covers around 200+ products under different phases of clinical development like
-
Late-stage products (Phase III)
-
Mid-stage products (Phase II)
-
Early-stage product (Phase I)
-
Pre-clinical and Discovery stage candidates
-
Discontinued & Inactive candidates
-
Route of Administration
Further Diabetes product details are provided in the report. Download the Diabetes pipeline report to learn more about the emerging Diabetes therapies
Some of the key companies in the Diabetes Therapeutics Market include:
Key companies developing therapies for Diabetes are - Novo Nordisk, Jiangsu Hengrui Medicine, Melior Pharmaceuticals, Adocia, Pfizer, AgeX Therapeutics, CarmotTherapeutics, Genexine, Inc., OPKO Health, Inc., VitNovo, Inc., Sciwind Biosciences, Caelus Health, SCOHIA PHARMA, Ionis Pharmaceuticals, Eli Lilly and Company, Oramed Pharmaceuticals, AstraZeneca, Aerami Therapeutics, Viking Therapeutics, VTV Therapeutics, AptamiR Therapeutics, Avolynt, Inc., Suzhou Yabao Pharmaceutical, CONJUCHEM, LLC., Hua Medicine, REMD Biotherapeutics, Novmeta Pharma, Afimmune Limited, Xeris Pharmaceuticals, Akros Pharma Inc., and others.
Diabetes Pipeline Analysis:
The Diabetes pipeline report provides insights into
-
The report provides detailed insights about companies that are developing therapies for the treatment of Diabetes with aggregate therapies developed by each company for the same.
-
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Diabetes Treatment.
-
Diabetes key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
-
Diabetes Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
-
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Diabetes market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Diabetes drugs and therapies
Diabetes Pipeline Market Drivers
-
Increasing prevalence, government bodies are collaborating with major market players for the launch of new products, increase in the demand for insulin over the world are some of the important factors that are fueling the Diabetes Market.
Diabetes Pipeline Market Barriers
-
However, side-effects associated with the treatment of Diabetes, a lack of knowledge about a healthy diet, medication initiation and other factors are creating obstacles in the Diabetes Market growth.
Scope of Diabetes Pipeline Drug Insight
-
Coverage: Global
-
Key Diabetes Companies: Eli Lilly and Company, Regor Pharmaceuticals Inc., AstraZeneca, Eccogene, Pfizer, Sciwind Biosciences USA Co., Ltd., MediciNova, Sparrow Pharmaceuticals, HighTide Biopharma Pty Ltd, Novo Nordisk A/S, Biomea Fusion Inc., Altimmune, Inc., Novartis, Amgen, Neuraly, Inc., Carmot Therapeutics, Inc., Inventiva Pharma, Inversago Pharma Inc, Applied Therapeutics, Inc., and others
-
Key Diabetes Therapies: Tirzepatide/LY3298176, Danuglipron, RGT001-075, AZD0186, ECC5004, PF-07081532, XW014, MN-001, SPI-62, HTD1801, Semaglutide, BMF-219, ALT-801, MBL949, LY3457263, AMG 133, DD01, CT-868, IVA337, INV-202, AT-001, and others
-
Diabetes Therapeutic Assessment: Diabetes current marketed and Diabetes emerging therapies
-
Diabetes Market Dynamics: Diabetes market drivers and Diabetes market barriers
Request for Sample PDF Report for Diabetes Pipeline Assessment and clinical trials
Table of Contents
1. Diabetes Report Introduction
2. Diabetes Executive Summary
3. Diabetes Overview
4. Diabetes- Analytical Perspective In-depth Commercial Assessment
5. Diabetes Pipeline Therapeutics
6. Diabetes Late Stage Products (Phase II/III)
7. Diabetes Mid Stage Products (Phase II)
8. Diabetes Early Stage Products (Phase I)
9. Diabetes Preclinical Stage Products
10. Diabetes Therapeutics Assessment
11. Diabetes Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Diabetes Key Companies
14. Diabetes Key Products
15. Diabetes Unmet Needs
16 . Diabetes Market Drivers and Barriers
17. Diabetes Future Perspectives and Conclusion
18. Diabetes Analyst Views
19. Appendix
20. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
